MERXIN
LIVE

Serial Number

79229680

Owner

Merxin Ltd

Attorney

Geza C. Ziegler, Jr.

Filing Date

Jan 18, 2018

Add to watchlist:

No watchlists yet
View on USPTO

MERXIN Trademark

Serial Number: 79229680 • Registration: 5730393

MERXIN is a trademark filed by Merxin Ltd on January 18, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Merxin Ltd (3 trademarks)

King's Lynn Innovation Centre
King's Lynn, Norfolk PE30 5BY , GB

Entity Type: 99

Trademark Details

Filing Date

January 18, 2018

Registration Date

April 23, 2019

Published for Opposition

February 5, 2019

Goods & Services

[ Vials for scientific purposes being laboratory equipment; Vials for laboratory use; Glass tubes for scientific purposes being laboratory equipment ] * Laboratory equipment for scientific purposes, namely, vials *

[ Pharmaceuticals for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for inhalers, namely, medical pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders structured for delivery into the body by nebulizer, aerosol, or dry powder, via the lungs or via the nasal passageway; Dietary supplements; Pharmaceutical products for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders ]

[ Pharmaceutical compounding services; Pharmaceutical compounding consultation services; Pharmaceutical compounding advisory services; Medical services; Veterinary services; Hygienic and beauty care for animals; Hygienic and beauty care for humans ]

* medical inhalers that are sold empty and in bulk via business-to-business transactions through business-to-business channels of trade * [ [ Surgical, medical, dental and veterinary apparatus and instruments, namely, injection devices for administering drugs sold empty; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Medical syringes sold empty for administering pharmaceuticals; Medical apparatus for introducing pharmaceutical preparations into the human body; Inhalers for medical use; ] Medical inhalers * Sold Empty * [ ; Respiratory monitors for medical use; Apparatus for measuring lung function; Spirometers for examining the function of the lungs; Spirometers; Spirometer mouth pieces and tubing; breath gas analyzers for medical diagnostics; Replacement cartridges for medical inhalers sold empty; Nebulizer for administering medication in the form of a mist inhaled into the lungs, for treatment of asthma and respiratory diseases ] ]

* design and development of medical inhalers sold empty and in bulk to third-party drug manufacturers and not for sale directly to end users * [ Scientific and technological services, namely, research and design in the field of drug delivery via the lungs or via the nasal passageway; Scientific and technological design of new products for others; Advisory services relating to [ design engineering ] * design of new products for others * ; Advisory services relating to [ product testing ] * testing of new products for others * ; Product design and development in the field of drug delivery via the lungs or via the nasal passageway; New product design services, namely, analysis and evaluation of product design; [ engineering design and consultancy ] * new product design and consultancy services * ; Professional consultancy relating to medical technology; [ engineering project management services, not for business purposes; Engineering research ] * project management services in the field of medical and pharmaceutical engineering, not for business purposes; Scientific research in the field of medical and pharmaceutical engineering * ; Pharmaceutical research and development services; research and development for the pharmaceutical industry; Research relating to medicines ]

Filing History

NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Jul 17, 2025 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Jul 17, 2025 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jul 15, 2025 APRE
TEAS SECTION 71 & 15 RECEIVED
Apr 22, 2025 ES75
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 17, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Apr 17, 2025 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Apr 17, 2025 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 17, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 17, 2025 REAP
NEW REPRESENTATIVE AT IB RECEIVED
Jun 16, 2024 NREP
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
May 2, 2024 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Apr 23, 2024 INPR
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Apr 23, 2024 REM3
NOTICE OF PARTIAL CANCELLATION SEC. 7 SURRENDER EMAILED
Aug 24, 2023 NCP7
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 23, 2023 APRE
CANCELLED SEC. 7 - PARTIAL
Aug 23, 2023 C7P.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 22, 2023 APRE
TEAS SECTION 7 REQUEST RECEIVED
May 15, 2023 ES7R
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
Apr 11, 2023 NURC
AMENDMENT UNDER SECTION 7 - PROCESSED
Mar 7, 2023 A7OK
ASSIGNED TO PARALEGAL
Mar 6, 2023 PLGL
TEAS SECTION 7 REQUEST RECEIVED
Feb 15, 2023 ES7R
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Aug 23, 2022 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Jul 9, 2022 INPR
AMENDMENT UNDER SECTION 7 - PROCESSED
Jan 5, 2022 A7OK
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Jan 4, 2022 EROP
POST REGISTRATION ACTION MAILED - SEC. 7
Jan 3, 2022 PRAM
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 3, 2022 APRE
OTQR WITHDRAWAL FROM PUBLICATION
Nov 24, 2021 WDRL
NOTICE OF PARTIAL CANCELLATION SEC. 7 SURRENDER EMAILED
Oct 27, 2021 NCP7
POST REGISTRATION ACTION CORRECTION
Oct 26, 2021 XXXX
CANCELLED SEC. 7 - PARTIAL
Oct 26, 2021 C7P.
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Oct 22, 2021 EROP
POST REGISTRATION ACTION MAILED - SEC. 7
Oct 18, 2021 PRAM
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 14, 2021 APRE
TEAS SECTION 7 REQUEST RECEIVED
May 18, 2021 ES7R
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 18, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 18, 2021 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 18, 2021 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 18, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 18, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 18, 2021 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 18, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 18, 2021 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 18, 2021 ECDR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
May 18, 2021 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 18, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 18, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 18, 2021 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 30, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 14, 2019 FICS
FINAL DISPOSITION PROCESSED
Aug 14, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 23, 2019 FICR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 14, 2019 ADCH
REGISTERED-PRINCIPAL REGISTER
Apr 23, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 5, 2019 NPUB
PUBLISHED FOR OPPOSITION
Feb 5, 2019 PUBO
NOTIFICATION PROCESSED BY IB
Feb 2, 2019 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 16, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 16, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 16, 2019 NONP
ASSIGNED TO LIE
Dec 28, 2018 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 10, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 10, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 10, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 10, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 10, 2018 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 27, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 26, 2018 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 26, 2018 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 24, 2018 GNFN
FINAL REFUSAL E-MAILED
Jul 24, 2018 GNFR
FINAL REFUSAL WRITTEN
Jul 24, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 29, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 29, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 29, 2018 TROA
REFUSAL PROCESSED BY IB
Jun 23, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 1, 2018 RFCS
REFUSAL PROCESSED BY MPU
Jun 1, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 24, 2018 RFCR
NON-FINAL ACTION WRITTEN
May 23, 2018 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
May 3, 2018 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 29, 2018 RFCR
NON-FINAL ACTION WRITTEN
Apr 28, 2018 CNRT
ASSIGNED TO EXAMINER
Apr 27, 2018 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 10, 2018 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 6, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 5, 2018 REPR